LAKESHA JONES: Open Payments
NPI 1649804469 · HUNTINGTON BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$819 in 45 payments from 9 companies in 2025. Trend: 2023 $1,454 · 2024 $1,730 · 2025 $819
Food & beverage: $819
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $273 |
| Teva Pharmaceuticals USA, Inc. | 16 | $262 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Neurocrine BioSciences, Inc. | 2 | $61 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Alkermes, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
Products named: VRAYLAR, UZEDY, AUSTEDO XR, INGREZZA, INVEGA SUSTENNA, CAPLYTA, COBENFY, REXULTI.
Industry payments across CA — which companies pay providers there.
